ArticlePulmonary circulation2026
The NLRP3 Inflammasome Increases Pulmonary Vascular Remodeling in Experimental Pulmonary Arterial Hypertension.
Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The NLRP3 Inflammasome Increases Pulmonary Vascular Remodeling in Experimental Pulmonary Arterial Hypertension.Pulmonary circulation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a progressive vasculopathy leading to right-sided heart failure. We have shown previously that the (NOD-like-receptor-3) NLRP3 inflammasome is activated in end-stage disease of the monocrotaline and aortocaval shunt (MCT/ACS) neointimal PAH rat model. The NLRP3 and absent-in-melanoma 2 (AIM2) inflammasomes mediate the secretion of interleukin (IL)-1β and IL-18. We investigated the role of the NLRP3 inflammasome in PAH rats and the presence of NLRP3 and AIM2 in PAH rat and pediatric patient lungs. For a natural history study, we assessed inflammasome activation by Western blot at different disease stages in the MCT/ACS neointimal PAH rat model. To assess the role of the inflammasome in PAH, we treated PAH rats with or without the NLRP3 inflammasome inhibitor MCC950 and assessed vascular remodeling employing hematoxylin and eosin staining on rat lungs. Lung sections from patients who had undergone lung transplantation were stained for NLRP3 and AIM2 using immunofluorescence. We found that inflammasome activation in lungs of PAH rats, reflected by cleaved caspase-1, IL-1β, and IL-18, increased over time, reaching significance for cleaved caspase-1 and IL-18 in end-stage PAH. The NLRP3 inflammasome inhibitor MCC950 suppressed vascular remodeling but not hemodynamic variables compared to control PAH rats. We detected NLRP3
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.